ReviewCureus2026
Testosterone Therapy and Tendon Injury: Clinical Evidence, Biological Mechanisms, and Sports Medicine Implications.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testosterone therapy increases lean mass and can improve muscle strength in men with hypogonadism. This review examines the relationship between testosterone therapy, tendon adaptation, and tendon injury, including the possibility of a mismatch between changes in muscle strength and tendon capacity. This narrative review critically evaluates the clinical and experimental evidence relating testosterone exposure to tendon injury. The present review focuses specifically on tendon-related safety and is not intended to assess the overall benefit-risk profile of testosterone therapy. Prescription-based studies have identified associations with distal biceps, rotator cuff, quadriceps, patellar, and Achilles tendon injuries. The magnitude of association varies considerably, with modest elevations in broad analyses and larger relative estimates in some site-specific studies. Absolute event rates are generally low, and the available studies cannot establish causation. Important limitations include incomplete information about treatment indications, testosterone concentrations, dosage, adherence, formulation, physical activity, pre-existing tendinopathy, and undisclosed anabolic-androgenic steroid use. Evidence from supraphysiologic androgen exposure provides greater biological plausibility but cannot be directly extrapolated to physiologic testosterone replacement. Potential biological mechanisms involving collagen synthesis, matrix remodelling, and tendon mechanical properties are also examined. No clinical evidence establishes a dose-response relationship or demonstrates that topical treatment, smaller injections, or more frequent dosing reduces tendon risk. Testosterone improves bone mineral density and estimated bone strength, but fracture prevention has not been demonstrated. Overall, a small increase in tendon injury risk with testosterone therapy is plausible, particularly in highly active individuals undergoing rapid increases in loading, but the evidence remains observational and substantially confounded. Clinicians should provide proportionate counselling without discouraging appropriately indicated treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.